|
Affiliation |
Faculty of Medicine School of Medicine Department of Internal Medicine, Hematology, Diabetes, and Endocrinology |
|
Title |
Lecturer |
|
External Link |
|
UENO Hiroaki
|
|
|
Research Areas 【 display / non-display 】
-
Life Science / Metabolism and endocrinology
Papers 【 display / non-display 】
-
Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers
Kameda T., Utsunomiya A., Otsuka N., Kubuki Y., Uchida T., Shide K., Kamiunten A., Nakano N., Tokunaga M., Miyazono T., Ito Y., Yonekura K., Kawakita T., Akizuki K., Tahira Y., Karasawa M., Hidaka T., Konagata A., Taniguchi N., Nagatomo Y., Kogo F., Shimizu K., Ueno H., Ishizaki J., Takahashi N., Ikei Y., Hidaka M., Yamaguchi H., Shimoda K.
BMC Infectious Diseases 24 ( 1 ) 96 2024.12
Language：English Publishing type：Research paper (scientific journal) Publisher：BMC Infectious Diseases
Background: Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown. Methods: To investigate humoral immunity after COVID-19 vaccination in HTLV-1 carriers, a multicenter, prospective observational cohort study was conducted at five institutions in southwestern Japan, an endemic area for HTLV-1. HTLV-1 carriers and HTLV-1-negative controls were enrolled for this study from January to December 2022. During this period, the third dose of the COVID-19 vaccine was actively administered. HTLV-1 carriers were enrolled during outpatient visits, while HTLV-1-negative controls included health care workers and patients treated by participating institutions for diabetes, hypertension, or dyslipidemia. The main outcome was the effect of HTLV-1 infection on the plasma anti-COVID-19 spike IgG (IgG-S) titers after the third dose, assessed by multivariate linear regression with other clinical factors. Results: We analyzed 181 cases (90 HTLV-1 carriers, 91 HTLV-1-negative controls) after receiving the third dose. HTLV-1 carriers were older (median age 67.0 vs. 45.0 years, p < 0.001) and more frequently had diabetes, hypertension, or dyslipidemia than did HTLV-1-negative controls (60.0% vs. 27.5%, p < 0.001). After the third dose, the IgG-S titers decreased over time in both carriers and controls. Multivariate linear regression in the entire cohort showed that time since the third dose, age, and HTLV-1 infection negatively influenced IgG-S titers. After adjusting for confounders such as age, or presence of diabetes, hypertension, or dyslipidemia between carriers and controls using the overlap weighting propensity score method, and performing weighted regression analysis in the entire cohort, both time since the third dose and HTLV-1 infection negatively influenced IgG-S titers. Conclusions: The humoral immunity after the third vaccination dose is impaired in HTLV-1 carriers; thus, customized vaccination schedules may be necessary for them.
-
Impact of the lipase inhibitor orlistat on the human gut microbiota Reviewed
Uehira Y., Ueno H., Miyamoto J., Kimura I., Ishizawa Y., Iijima H., Muroga S., Fujita T., Sakai S., Samukawa Y., Tanaka Y., Murayama S., Sakoda H., Nakazato M.
Obesity Research and Clinical Practice 17 ( 5 ) 411 - 420 2023.9
Language：English Publishing type：Research paper (scientific journal) Publisher：Obesity Research and Clinical Practice
Orlistat, an anti-obesity agent, inhibits the metabolism and absorption of dietary fat by inactivating pancreatic lipase in the gut. The effect of orlistat on the gut microbiota of Japanese individuals with obesity is unknown. This study aimed to explore the effects of orlistat on the gut microbiota and fatty acid metabolism of Japanese individuals with obesity. Fourteen subjects with visceral fat obesity (waist circumference ≥85 cm) took orlistat orally at a dose of 60 mg, 3 times a day for 8 weeks. Body weight; waist circumference; visceral fat area; levels of short-chain fatty acids, gut microbiota, fatty acid metabolites in the feces, and gastrointestinal hormones; and adverse events were evaluated. Body weight, waist circumference, and blood leptin concentrations were significantly lower after orlistat treatment (mean ± standard deviation, 77.8 ± 9.1 kg; 91.9 ± 8.7 cm; and 4546 ± 3211 pg/mL, respectively) compared with before treatment (79.4 ± 9.0 kg; 94.4 ± 8.0 cm; and 5881 ± 3526 pg/mL, respectively). Significant increases in fecal levels of fatty acid metabolites (10-hydroxy-cis-12-octadecenoic acid, 10-oxo-cis-12-octadecenoic acid, and 10-oxo-trans-11-octadecenoic acid) were detected. Meanwhile, no significant changes were found in abdominal computed tomography parameters, blood marker levels, or short-chain fatty acid levels in the feces. Gut microbiota analysis revealed that some study subjects had decreased abundance of Firmicutes, increased abundance of Bacteroidetes, and increased α-diversity indices (Chao1 and ACE) after 8 weeks of treatment. The levels of Lactobacillus genus and Lactobacillus gasseri were significantly higher after 8 weeks of treatment. None of the subjects discontinued treatment or experienced severe adverse events. This study suggested that orlistat might alter gut microbiota composition and affect the body through fatty acid metabolites produced by the modified gut bacteria.
-
Association between personality traits and glycemic control after inpatient diabetes education.
Uchida T, Ueno H, Konagata A, Nakamura T, Taniguchi N, Nabekura H, Kogo F, Nagatomo Y, Tanaka Y, Shimizu K, Shiiya T, Yamaguchi H, Shimoda K
Metabolism open 18 100244 2023.6
Language：English Publishing type：Research paper (scientific journal)
-
Uchida T., Ueno H., Konagata A., Taniguchi N., Kogo F., Nagatomo Y., Shimizu K., Yamaguchi H., Shimoda K.
Diabetes Therapy 14 ( 6 ) 1075 - 1076 2023.6
Language：English Publishing type：Research paper (scientific journal) Publisher：Diabetes Therapy
-
Association of Serum Levels of Cholesterol Absorption and Synthesis Markers with the Presence of Cardiovascular Disease: The CACHE Study CVD Analysis
Katsuki Shunsuke, Matoba Tetsuya, Akiyama Yusuke, Yoshida Hiroshi, Kotani Kazuhiko, Fujii Hisako, Harada-Shiba Mariko, Ishibashi Yutaka, Ishida Tatsuro, Ishigaki Yasushi, Kabata Daijiro, Kihara Yasuki, Kurisu Satoshi, Masuda Daisaku, Matsuki Kota, Matsumura Takeshi, Mori Kenta, Nakagami Tomoko, Nakazato Masamitsu, Taniuchi Satsuki, Ueno Hiroaki, Yamashita Shizuya, Yoshida Hisako, Tsutsui Hiroyuki, Shoji Tetsuo
Journal of Atherosclerosis and Thrombosis advpub ( 0 ) 2023.4
Language：English Publishing type：Research paper (scientific journal) Publisher：Japan Atherosclerosis Society
DOI： 10.5551/jat.64119
Books 【 display / non-display 】
-
食欲調節機構
上野浩晶（ Role： Sole author）
肥満症診療ガイドライン2022, 日本肥満学会 編、ライフサイエンス出版 2022.12
Language：Japanese Book type：Scholarly book
-
DPP-4阻害薬
上野浩晶、中里雅光（ Role： Joint author）
南江堂 2021.10
Language：Japanese Book type：Scholarly book
-
脳内炎症と肥満
上野浩晶、中里雅光（ Role： Joint author）
羊土社 2021.3
Language：Japanese Book type：Scholarly book
-
SGLT2阻害薬の体重減少作用について
上野浩晶、中里雅光（ Role： Joint author）
中外医学社 2020.4
Responsible for pages：51-57 Language：Japanese Book type：Scholarly book
-
カンナビノイド系：内科学書 改訂第8版
上野浩晶、中里雅光（ Role： Joint author）
中山書店 2020
Responsible for pages：20200000 Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
食事療法の一工夫 Invited
上野浩晶
はまゆう ( 131 ) 3 - 4 2022.4
Authorship：Lead author Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (other)
-
高度肥満に対する内科的治療が奏功している例とリバウンド例 Invited
上野浩晶、中里雅光
Medical Practice 38 ( 7 ) 1096 - 1101 2021.7
Authorship：Lead author Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Liver-expressed antimicrobial peptide2(LEAP-2)の成長ホルモン分泌における生理的役割および病態との関連
迫田秀之, 酒井克也, 鍋倉弘樹, 谷田亮太, 上野浩晶, 山口秀樹
成長科学協会研究年報 ( 44 ) 2021
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal)
-
高PRL性無月経を来した維持透析1型糖尿病へのドパミン製剤の治療経験
山口 秀樹, 松下 隆司, 内田 泰介, 田中 友梨, 古郷 芙未子, 鍋倉 弘樹, 上平 雄大, 迫田 秀之, 上野 浩晶, 中里 雅光
糖尿病 63 ( 4 ) 246 - 246 2020.4
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：(一社)日本糖尿病学会
-
GLP-1およびインスリン製剤の使い方 Invited
上野 浩晶
糖尿病 63 ( 4 ) 213 - 214 2020.4
Authorship：Lead author Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：(一社)日本糖尿病学会
Presentations 【 display / non-display 】
-
外来通院する高齢糖尿病患者の身体機能およびロコモ度の特徴について
後藤夏季、上野浩晶、宮崎茂明、荒川英樹、帖佐悦男
第7回日本リハビリテーション医学会秋季学術集会 2023.11
Event date： 2023.11.3 - 2023.11.5
Language：Japanese Presentation type：Poster presentation
-
肥満合併糖尿病に対する内科治療におけるパーソナリティ特性の影響の検討
内田 泰介、上野浩晶、積島宏昂、積島愛加理、中村孝之、古郷芙美子、清水浩一郎、山口秀樹、下田和哉
第30回西日本肥満研究会 2023.7.23
Event date： 2023.7.22 - 2023.7.23
Language：Japanese Presentation type：Oral presentation (general)
-
糖尿病に対する教育入院後の血糖コントロールとパーソナリティ特性の関係に関する前向き観察研究
内田 泰介、上野浩晶、中村孝之、谷口宗典、古郷芙美子、鍋倉弘樹、長友雄麻、田中友梨、清水浩一郎、山口秀樹、下田和哉
第96回日本内分泌学会学術総会 2023.6.3
Event date： 2023.6.1 - 2023.6.3
Language：Japanese Presentation type：Oral presentation (general)
-
ンクレチン関連薬から変更した場合の経口セマグルチドおよびセマグルチド皮下注射の治療効果に関する後ろ向き観察研究
古郷芙美子、上野浩晶、内田泰介、小永田綾香、谷口宗典、長友雄麻、清水浩一郎、山口秀樹、下田和哉
第66回日本糖尿病学会年時学術集会 2023.5.11
Event date： 2023.5.11 - 2023.5.13
Language：Japanese Presentation type：Oral presentation (general)
-
イメグリミンの血管内皮機能及び血糖値スパイクへの改善効果に関する単施設前向き観察研究
上野浩晶、内田泰介、小永田綾香、谷口宗典、古郷芙美子、長友雄麻、清水浩一郎、山口秀樹、下田和哉
第66回日本糖尿病学会年時学術集会 2023.5.13
Event date： 2023.5.11 - 2023.5.13
Language：Japanese Presentation type：Oral presentation (general)
Awards 【 display / non-display 】
-
日本糖尿病学会九州支部賞
2015.11 日本糖尿病学会九州支部
上野浩晶
Award type：Award from Japanese society, conference, symposium, etc. Country：Japan
-
博慈会オープンセサミ賞
2014.2 博慈会
上野浩晶
Award type：Award from publisher, newspaper, foundation, etc. Country：Japan
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
グレリン併用運動療法の多面的抗生活習慣病作用に関する研究
2011.04 - 2014.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
糖尿病を初めとする生活習慣病の治療に関して、グレリンの持つ成長ホルモン(GH)非依存性のグレリン特異的作用、および運動時に惹起されるＧＨ分泌亢進の増強を介した糖・脂質代謝改善と体組成の改善作用（除脂肪体重の増加と脂肪重量の減少）を検証する。また、グレリンが糖尿病性神経障害、腎症および動脈硬化性病変に対する改善作用を持ち、多面的な抗生活習慣病薬となり得ることを検討する。
-
新規ペプチド オベスタチンおよびグレリンの肥満に対する病態生理学的意義の検討
2007.04 - 2009.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
胃から産生・分泌される新規ペプチドであるオベスタチンおよびグレリンの肥満に対する病態生理学的意義の検討を行う